Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Non Operating Income (2019 - 2025)

Allogene Therapeutics' Other Non Operating Income history spans 7 years, with the latest figure at -$81000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 92.79% year-over-year to -$81000.0; the TTM value through Sep 2025 reached -$2.0 million, up 77.71%, while the annual FY2024 figure was -$3.9 million, 78.02% up from the prior year.
  • Other Non Operating Income for Q3 2025 was -$81000.0 at Allogene Therapeutics, down from -$43000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.1 million in Q1 2023 and bottomed at -$6.9 million in Q4 2023.
  • The 5-year median for Other Non Operating Income is -$910000.0 (2021), against an average of -$930789.5.
  • The largest YoY upside for Other Non Operating Income was 318.5% in 2023 against a maximum downside of 463.74% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$1.2 million in 2021, then dropped by 5.94% to -$1.2 million in 2022, then plummeted by 463.74% to -$6.9 million in 2023, then soared by 71.85% to -$2.0 million in 2024, then skyrocketed by 95.85% to -$81000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Other Non Operating Income are -$81000.0 (Q3 2025), -$43000.0 (Q2 2025), and $92000.0 (Q1 2025).